QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序作者升序作者降序提交时间升序提交时间降序题名升序题名降序 Small molecules as inhibitors of PCSK9: Current status and future challenges 期刊论文 European Journal of Medicinal Chemistry, 2019, 卷号: Vol.162, 页码: 212-233 作者:  Shengtao Xu;  Shanshan Luo;  Zheying Zhu;  Jinyi Xu 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/13 PCSK9  protein  Inhibitor  Small-molecule  LDL-C  Hypercholesterolemia  Natural  products  Patent   Small molecules as inhibitors of PCSK9: Current status and future challenges 期刊论文 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: Vol.162, 页码: 212-233 作者:  Xu, Shengtao;  Luo, Shanshan;  Zhu, Zheying;  Xu, Jinyi 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/17 PCSK9 protein  Inhibitor  Small-molecule  LDL-C  Hypercholesterolemia  Natural products  Patent   Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial 期刊论文 CLINICAL CARDIOLOGY, 2018, 卷号: 41, 期号: 9 作者:  Lorenzatti, Alberto J.;  Eliaschewitz, Freddy G.;  Chen, Yundai;  Fialkow, Jonathan;  Lu, Juming 收藏  |  浏览/下载：14/0  |  提交时间：2019/12/05 diabetes  diabetic dyslipidemia  dyslipidemia  hypercholesterolemia  monoclonal antibody  PCSK9  PCSK9 inhibitor   The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors 期刊论文 Pharmacological Research, 2013, 卷号: 73, 页码: 27-34 作者:  Shen, Li;  Peng, Hongchun;  Xu, Danyan*;  Zhao, Shuiping 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03 Proprotein convertase subtilisin/kexin 9  LDL receptor  LDL cholesterol  Gain-of-function mutation  PCSK9 inhibitor  Dyslipidemia